In the regulatory filing, the company said “Earlier during the year, the Company entered into a non-exclusive voluntary licensing agreement with MSD Pharmaceuticals for their investigational antiviral drug (Covid-19) molnupiravir. The Company has completed the trials for molnupiravir in mild Covid-19 patients as per protocol and the results have come out exceedingly well. The data for the same has been submitted to the Drug Controller General of India (DCGI) already.”
The stock is currently trading at Rs724.50 up by Rs4.1 or 0.57% from its previous closing of Rs720.40 on the BSE.
“We refer to your email/letter dated October 11, 2021, seeking clarification on the captioned media report. The Company has also conducted the trials for molnupiravir in 100 moderate Covid-19 patients.”
We have faced challenges in patient recruitment at this juncture and are evaluating further course of action,” the company added.
However, as the matter was not material in nature, the same did not warrant disclosure to the Stock Exchanges, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Aurobindo Pharma said.